Spondyloarthritis & psoriatic arthritis
Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response
An erratum to this article was published (Scand J Rheumatol, Sep 2024 ↗)
Authors' conclusion
When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.
Study context
- Population
- Biologic-naïve patients with PsA, diagnosed by a rheumatologist, initiating first tumour necrosis factor inhibitor (TNFi) across 12 European registries874 with baseline entheses assessment
- Participants
- 10,547 patients
- Exposure
- PsA with vs without enthesitis at first TNFi initiation
- Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)n = 485
- Spondyloarthritis Research Consortium of Canada (SPARCC)n = 389
- Outcome
- Registration and prevalence of enthesitis at first TNFi initiation (baseline)
- Follow-up
- Baseline
Methodological detailsmulticentre, 12 European registries, European Spondyloarthritis (EuroSpA) Research Collaboration Network
- Multicentre
- 12 European registries
- EuroSpA Research Collaboration Network
Main finding
As reported in the abstract
Enthesitis detected at baseline
| Group | Value | Mean score ± SD |
|---|---|---|
| MASES | 35% | 3.1 ± 2.4 |
| SPARCC | 61% | 4 ± 3.4 |
Value
MASES35%
SPARCC61%
Mean score ± SD
MASES3.1 ± 2.4
SPARCC4 ± 3.4
- Entheseal assessment registered
- 1357
Observational data: associations, not effects.
Further findings
Resolution of enthesitis following TNFi-1 · follow-up
| Outcome | MASES | SPARCC |
|---|---|---|
| Achilles enthesitis (most frequent), unilateral/bilateral · baseline | 28%/9% | 48%/18% |
| Site-specific enthesitis resolution following TNFi-1 · follow-up | 82-100% | 63-80% |
- Resolution of enthesitis following TNFi (TNFi-1): baseline and follow-up scores available for 100/105 patients
Site-specific enthesitis resolution following TNFi-1 · follow-up
- Resolution overall lower at SPARCC (peripheral) than MASES (mainly axial) sites
Disease activity and patient-reported outcomes (PROs), with vs without enthesitis · baseline
- Disease activity and PROs worse in patients with vs without enthesitis
Original publication
Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response. Scand J Rheumatol. Published 21 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →